Healthcare costs of congenital cytomegalovirus (cCMV) disease in infants during the first two years of life: a retrospective German claims database analysis

Anna-Janina Stephan; Marion de Lepper; Regine Wölle; Agnes Luzak; Wei Wang; Christian Jacob; Kim Maren Schneider; Horst Buxmann; Rangmar Goelz; Klaus Hamprecht; Peter Kummer; Susanne Modrow; Wolfgang Greiner; Miriam Reuschenbach

doi:10.1186/s12962-022-00411-x

Healthcare costs of congenital cytomegalovirus (cCMV) disease in infants during the first two years of life: a retrospective German claims database analysis

Cost Eff Resour Alloc. 2023 Jan 23;21(1):8. doi: 10.1186/s12962-022-00411-x.

Authors

Affiliations

¹ Department of Market Access, MSD Sharp & Dohme GmbH, Munich, Germany.
² Department of Medical Affairs, MSD Sharp & Dohme GmbH, Munich, Germany. marion.de.lepper@msd.de.
³ Center for Observational and Real-World Evidence (CORE), Merck & Co., Inc., Rahway, NJ, USA.
⁴ EU Real World Evidence, Xcenda GmbH, Hannover, Germany.
⁵ Department for Children and Adolescents, Division for Neonatology, Main-Kinzig-Kliniken GmbH, Gelnhausen, Germany.
⁶ Department of Neonatology, University Children's Hospital, Tuebingen, Germany.
⁷ Institute for Medical Virology and Epidemiology of Viral Diseases, University of Tuebingen, Tuebingen, Germany.
⁸ Section of Phoniatrics and Pediatric Audiology, Department of Otolaryngology, University Hospital Regensburg, Regensburg, Germany.
⁹ Institute of Medical Microbiology and Hygiene, University Hospital Regensburg, Regensburg, Germany.
¹⁰ Department of Health Economics and Health Care Management, Bielefeld School of Public Health, Bielefeld University, Bielefeld, Germany.
¹¹ Global Medical and Scientific Affairs, MSD Sharp & Dohme GmbH, Munich, Germany.

^# Contributed equally.

Abstract

Background: Congenital cytomegalovirus (cCMV) infection can cause severe neurological damage, growth retardation, hearing loss, and microcephaly in infants. We aimed at assessing healthcare costs of infants with recorded cCMV diagnosis in an administrative claims database in the first 2 years of life.

Methods: We conducted a retrospective, controlled cohort study using German claims data from the Institute for Applied Health Research Berlin (InGef) database. Incremental healthcare costs during the first and second year of life were assessed by matching (1:60) infants with cCMV diagnoses ≤ 90 days after birth (cCMV₉₀ cohort) to infants without cCMV diagnosis ("representative" controls) and infants with cCMV diagnoses ≤ 21 days after birth plus specific symptoms (cCMV_21-S) to infants without cCMV and any ICD-10-GM records (besides Z00-Z99) until 4^th preventive health check-up ("healthy" controls). Due to missing data, mean imputation was applied for aids and remedies costs.

Results: We identified 54 and 24 infants born 2014-2018 for the cCMV₉₀ and cCMV_21-S cohorts, respectively. During the first year, mean (median) healthcare costs were significantly higher in cCMV₉₀ cases vs. "representative" controls (€22,737 (€9759) vs. €3091 (€863), p < 0.001), with 87.2% inpatient costs. Healthcare costs for cCMV_21-S cases compared to "healthy" controls were €34,498 (€20,924) vs. €680 (€569), p < 0.001. Differences decreased for both comparisons in the second year but remained statistically significant.

Conclusions: cCMV comprises a considerable economic burden for the German healthcare system (€19,646 to €33,818 higher mean costs for infants with recorded cCMV diagnosis in the first year of life). Attempts should be made to reduce this burden.

Keywords: Administrative data; Congenital CMV infection; Germany; Health economic burden; Newborns.